Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice

Impact of Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04049188

Acronym

SFPRT

Enrollment

Registered

2019-08-08

Start date

2020-01-01

Completion date

2021-12-31

Last updated

2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Metastatic

Keywords

Cancer Patients Hospice Care, Palliative Radiation Therapy

Brief summary

Feasibility study to report on the impact of ACCESS of single-fraction radiation therapy on cancer patients with bone metastases enrolled in hospice care.

Detailed description

Hospice care for terminally ill patients with metastatic cancer improves quality of life, pain control, and potentially also survival when patients are enrolled early.1-3 However, hospice programs are often seen by patients and their caregivers as the last resort after exhaustion of all effective treatment options. The need to revoke active treatment (for all hospice patients with cancer outside of the VA system) discourages hospice enrollment. This study aims to understand and analyze barriers to access specifically for short course palliative radiation therapy in cancer patients enrolled in hospice.

Interventions

RADIATIONSingle-Fraction Palliative Radiation Therapy

All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Solid Tumor Malignancies and Multiple Myeloma with Bone Metastases and Associated Bone Pain Enrolled in Hospice

Exclusion criteria

* Decisionally-Impaired Subjects, Pregnant Women

Design outcomes

Primary

Measure	Time frame	Description
Change in Opioid Use for Pain Management	Through study completion, an average of 1 year	Opioid Dosage (mg/day)

Secondary

Measure	Time frame	Description
Improved Quality of Life Measures	During study completion	Questionnaires using Herth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale
Improved Activities of Daily Living	During study completion	Questionnaires using Hearth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale

Countries

United States

Contacts

Primary ContactAndy Kyler, BSN, MBA

andy.kyler@carepartners.org5036192621

Backup ContactChrista Nicholas

Christa.Nicholas@carepartnersor.org5036469565

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026